Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medicinal Chemistry
  4. Fast Track Articles
  5. Fast Track Article
image of Oridonin Suppresses the Malignant Progression of Lung Cancer by Targeting S100A11

Abstract

Background

Lung cancer (LC) is the second most lethal cancer and efficient treatments are missing. Our understanding of the underlying pathogenic mechanisms remains limited. Oridonin is a compound extracted from the Chinese herb with anticancer properties. Nevertheless, its effects on LC and the underlying mechanisms remain unknown.

Methods

In the current research, A549 and Hcc1833 cells were treated with different doses of oridonin, and cell proliferation and migration were detected using CCK8, EdU, Transwell, and wound healing assays. A subcutaneous tumor and caudal vein metastasis model was generated to verify the inhibitory effects of oridonin on Hcc1833 tumor growth and metastasis . Proteomics analyses then were performed to examine the regulatory mechanism. LiP-SMap combined with microscale thermophoresis and molecular docking analyses were used to validate the relationship between oridonin and S100A11.

Result

Data showed that oridonin suppressed cell proliferation and migration depending on dose and suppressed tumor growth and invasion. LiP-SMap and molecular docking analyses confirmed that oridonin interacted with the Asn-53 residue of S100A11, which inhibited the activation of oridonin. S100A11 overexpression reversed the inhibitory effects of oridonin on cell proliferation and migration.

Conclusion

In conclusion, the data indicate that oridonin suppresses LC malignant progression by targeting S100A11.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673352893241228015939
2025-01-23
2025-07-06

  • From This Site

    /content/journals/cmc/10.2174/0109298673352893241228015939
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Bray F. Ferlay J. Soerjomataram I. Siegel R.L. Torre L.A. Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018 68 6 394 424 10.3322/caac.21492 30207593
    [Google Scholar]
  2. Megyesfalvi Z. Gay C.M. Popper H. Pirker R. Ostoros G. Heeke S. Lang C. Hoetzenecker K. Schwendenwein A. Boettiger K. Bunn P.A. Jr Renyi-Vamos F. Schelch K. Prosch H. Byers L.A. Hirsch F.R. Dome B. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J. Clin. 2023 73 6 620 652 10.3322/caac.21785 37329269
    [Google Scholar]
  3. Hwang T.L. Chang C.H. Oridonin enhances cytotoxic activity of natural killer cells against lung cancer. Int. Immunopharmacol. 2023 122 110669 10.1016/j.intimp.2023.110669 37480753
    [Google Scholar]
  4. Leiter A. Veluswamy R.R. Wisnivesky J.P. The global burden of lung cancer: Current status and future trends. Nat. Rev. Clin. Oncol. 2023 20 9 624 639 10.1038/s41571‑023‑00798‑3 37479810
    [Google Scholar]
  5. Liu D.L. Bu H.Q. Wang W.L. Luo H. Cheng B.N. Oridonin enhances the anti-tumor activity of gemcitabine towards pancreatic cancer by stimulating Bax- and Smac-dependent apoptosis. Transl. Cancer Res. 2020 9 7 4148 4161 10.21037/tcr‑19‑3000 35117784
    [Google Scholar]
  6. Wang Y. Lv H. Dai C. Wang X. Yin Y. Chen Z. Oridonin dose-dependently modulates the cell senescence and apoptosis of gastric cancer cells. Evid. Based Complement. Alternat. Med. 2021 2021 1 12 10.1155/2021/5023536 34795783
    [Google Scholar]
  7. Zhou J. Li Y. Shi X. Hao S. Zhang F. Guo Z. Gao Y. Guo H. Liu L. Oridonin inhibits tumor angiogenesis and induces vessel normalization in experimental colon cancer. J. Cancer 2021 12 11 3257 3264 10.7150/jca.55929 33976735
    [Google Scholar]
  8. Zhao Y. Xiao W. Peng W. Huang Q. Wu K. Evans C.E. Liu X. Jin H. Oridonin-Loaded nanoparticles inhibit breast cancer progression through regulation of ROS-related Nrf2 signaling pathway. Front. Bioeng. Biotechnol. 2021 9 600579 10.3389/fbioe.2021.600579 33898397
    [Google Scholar]
  9. Xu L. Bi Y. Xu Y. Zhang Z. Xu W. Zhang S. Chen J. Oridonin inhibits the migration and epithelial-to-mesenchymal transition of small cell lung cancer cells by suppressing FAK-ERK1/2 signalling pathway. J. Cell. Mol. Med. 2020 24 8 4480 4493 10.1111/jcmm.15106 32168416
    [Google Scholar]
  10. Yang H. Gao Y. Fan X. Liu X. Peng L. Ci X. Oridonin sensitizes cisplatin-induced apoptosis via AMPK/Akt/mTOR-dependent autophagosome accumulation in A549 cells. Front. Oncol. 2019 9 769 10.3389/fonc.2019.00769 31475112
    [Google Scholar]
  11. Li W. Han F. Tang K. Ding C. Xiong F. Xiao Y. Li C. Liang Q. Lee K.Y. Lee I.S. Gao H. Inhibiting NF-κB-S100A11 signaling and targeting S100A11 for anticancer effects of demethylzeylasteral in human colon cancer. Biomed. Pharmacother. 2023 168 115725 10.1016/j.biopha.2023.115725 37879212
    [Google Scholar]
  12. Zheng M. Meng H. Li Y. Shi J. Han Y. Zhao C. Chen J. Han J. Liang J. Chen Y. Liu Q. Wang Y. S100A11 promotes metastasis via AKT and ERK signaling pathways and has a diagnostic role in hepatocellular carcinoma. Int. J. Med. Sci. 2023 20 3 318 328 10.7150/ijms.80503 36860671
    [Google Scholar]
  13. Yang H. Lv H. Li H. Ci X. Peng L. Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-κB pathways. Cell Commun. Signal. 2019 17 1 62 10.1186/s12964‑019‑0366‑y 31186013
    [Google Scholar]
  14. Wang L. Zhao X. Ding J. Liu Y. Liu H. Zheng L. Zhao H. Sun Z. Li K. Cai J. Qiao T. Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice. Inflammopharmacology 2023 31 4 1993 2005 10.1007/s10787‑023‑01161‑9 37155118
    [Google Scholar]
  15. Zhou F. Gao H. Shang L. Li J. Zhang M. Wang S. Li R. Ye L. Yang S. Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer. J. Exp. Clin. Cancer Res. 2023 42 1 150 10.1186/s13046‑023‑02702‑4 37337284
    [Google Scholar]
  16. Min Chen Yahui Shen Oridonin represses lung cancer cell proliferation and migration by modulating AFAP1-AS1/IGF2BP1. Cell. Mol. Biol. 2024 70 6 108 113 10.14715/cmb/2024.70.6.17 38836673
    [Google Scholar]
  17. Gui Y. Cheng J. Chen Z. Oridonin improves the therapeutic effect of lentinan on lung cancer. Exp. Ther. Med. 2021 22 2 886 10.3892/etm.2021.10318 34194564
    [Google Scholar]
  18. Wang Y.Y. Lv Y.F. Lu L. Cai L. Oridonin inhibits mTOR signaling and the growth of lung cancer tumors. Anticancer Drugs 2014 25 10 1192 1200 10.1097/CAD.0000000000000154 25075795
    [Google Scholar]
  19. Li S. Shi D. Zhang L. Yang F. Cheng G. Oridonin enhances the radiosensitivity of lung cancer cells by upregulating Bax and downregulating Bcl‑2. Exp. Ther. Med. 2018 16 6 4859 4864 10.3892/etm.2018.6803 30546402
    [Google Scholar]
  20. Ji X. Qin X. Huang X. Wang W. Li H. Zheng C. Huang Y. S100A11: A potential carcinogen and prognostic marker that correlates with the immunosuppressive microenvironment in pan-cancer. J. Cancer 2023 14 1 88 98 10.7150/jca.78011 36605485
    [Google Scholar]
  21. Woo T. Okudela K. Mitsui H. Tajiri M. Rino Y. Ohashi K. Masuda M. Up-regulation of S100A11 in lung adenocarcinoma: Its potential relationship with cancer progression. PLoS One 2015 10 11 e0142642 10.1371/journal.pone.0142642 26544866
    [Google Scholar]
  22. Zhang L. Zhu T. Miao H. Liang B. The calcium binding protein S100A11 and its roles in diseases. Front. Cell Dev. Biol. 2021 9 693262 10.3389/fcell.2021.693262 34179021
    [Google Scholar]
  23. Ni H.M. Chao X. Ding W.X. S100A11 overexpression promotes fatty liver diseases via increased autophagy? Cell. Mol. Gastroenterol. Hepatol. 2021 11 3 885 886 10.1016/j.jcmgh.2020.11.013 33290740
    [Google Scholar]
  24. Wang H. Yin M. Ye L. Gao P. Mao X. Tian X. Xu Z. Dai X. Cheng H. S100A11 promotes glioma cell proliferation and predicts grade-correlated unfavorable prognosis. Technol. Cancer Res. Treat. 2021 20 15330338211011961 10.1177/15330338211011961 33902363
    [Google Scholar]
  25. Tu Y. Xie P. Du X. Fan L. Bao Z. Sun G. zhao P. Chao H. Li C. Zeng A. Pan M. Ji J. S100A11 functions as novel oncogene in glioblastoma via S100A11/ANXA2/NF-κB positive feedback loop. J. Cell. Mol. Med. 2019 23 10 6907 6918 10.1111/jcmm.14574 31430050
    [Google Scholar]
  26. Cui Y. Li L. Li Z. Yin J. Lane J. Ji J. Jiang W.G. Dual effects of targeting S100A11 on suppressing cellular metastatic properties and sensitizing drug response in gastric cancer. Cancer Cell Int. 2021 21 1 243 10.1186/s12935‑021‑01949‑1 33931048
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673352893241228015939
Loading
Oridonin Suppresses the Malignant Progression of Lung Cancer by Targeting S100A11
Bentham Science Publishers ; https://doi.org/10.2174/0109298673352893241228015939
/content/journals/cmc/10.2174/0109298673352893241228015939
/content/journals/cmc/10.2174/0109298673352893241228015939
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: S100A11 ; malignant progression ; lung cancer ; Oridoninm

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test